{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:31:44Z","timestamp":1785411104414,"version":"3.56.0"},"posted":{"date-parts":[[2026,1,12]]},"group-title":"Pharmacology and Toxicology","reference-count":63,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"award":["CA215081"],"award-info":[{"award-number":["CA215081"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["CA268513"],"award-info":[{"award-number":["CA268513"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Tumor resistance to radiotherapy continues to be a significant problem in improving cancer patient outcomes. To overcome radioresistance, drugs that sensitize cancer cells to ionizing radiation have been tested. In theory, radiosensitizers should increase irradiated tumor kill and improve patient outcomes. In practice, the clinical utility of such drugs is curtailed by radiosensitization of peri-tumoral normal tissues causing toxicities. To address these issues, we developed an activatable cell penetrating peptide-drug conjugate to deliver a small molecule radiosensitizer with spatial precision to tumors. The activatable cell penetrating peptide (ACPP) scaffold cloaks a cell penetrating peptide-drug conjugate until it is unmasked within tumors through matrix metalloproteinase cleavage. Using antibody-drug conjugate linker chemistry, we attached the potent ataxia-telangiectasia mutated (ATM) kinase inhibitor AZD0156 to ACPP and created ACPP-AZD0156. In immune-competent murine cancer models, tumor-targeted ACPP-AZD0156 in combination with ionizing radiation stimulated tumor immune infiltration by CD8+ T cells and increased tumor control when compared to non-targeted ATM inhibitor. Mechanistically, ACPP-AZD0156 radiosensitized tumor control was dependent on the adaptive arm of the immune system. Finally, the combination of radiotherapy and ACPP-AZD0156 potentiated immune checkpoint inhibitors that resulted in durable tumor control. The therapeutic synergies of ACPP targeted ATM inhibitor to radiosensitize and stimulate anti-tumor immune responses provides a rationale for developing tumor-targeted radiosensitizer drug conjugates that restrict radiosensitization to cancer cells that then engages anti-tumor immune responses to improve cancer patient outcomes.<\/jats:p>","DOI":"10.64898\/2026.01.09.698736","type":"posted-content","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T14:20:17Z","timestamp":1768227617000},"source":"Crossref","is-referenced-by-count":0,"title":["Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6267-0312","authenticated-orcid":false,"given":"Kanika","family":"Dhawan","sequence":"first","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA"},{"name":"UC San Diego, Moores Cancer Center, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Allevato","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Lesperance","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F.","family":"Camargo","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus M.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Mortaja","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamdad","family":"Zareh","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina V.","family":"Hingorani","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5150-4482","authenticated-orcid":false,"given":"J. Silvio","family":"Gutkind","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of California San Diego, La Jolla, CA 92093, USA"},{"name":"UC San Diego, Moores Cancer Center, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7964-1315","authenticated-orcid":false,"given":"Sunil J.","family":"Advani","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA"},{"name":"UC San Diego, Moores Cancer Center, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026020501342148000_2026.01.09.698736v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4003"},{"key":"2026020501342148000_2026.01.09.698736v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.03.001"},{"key":"2026020501342148000_2026.01.09.698736v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0714"},{"key":"2026020501342148000_2026.01.09.698736v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70025-7"},{"key":"2026020501342148000_2026.01.09.698736v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106133242402"},{"issue":"4","key":"2026020501342148000_2026.01.09.698736v1.6","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"2026020501342148000_2026.01.09.698736v1.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199206113262403"},{"key":"2026020501342148000_2026.01.09.698736v1.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2692"},{"key":"2026020501342148000_2026.01.09.698736v1.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106106"},{"key":"2026020501342148000_2026.01.09.698736v1.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7629"},{"key":"2026020501342148000_2026.01.09.698736v1.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904153401501"},{"key":"2026020501342148000_2026.01.09.698736v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3007"},{"issue":"10","key":"2026020501342148000_2026.01.09.698736v1.13","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/S1470-2045(24)00199-2","article-title":"Best practices and novel approaches for the preclinical development of drug-radiotherapy combinations for cancer treatment","volume":"25","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026020501342148000_2026.01.09.698736v1.14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41698-025-00885-x","article-title":"Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies","volume":"9","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026020501342148000_2026.01.09.698736v1.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3229"},{"key":"2026020501342148000_2026.01.09.698736v1.16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005148"},{"issue":"11","key":"2026020501342148000_2026.01.09.698736v1.17","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2217\/fon.11.111","article-title":"DNA damage response and repair: insights into strategies for radiation sensitization of gliomas","volume":"7","year":"2011","journal-title":"Future Oncol"},{"key":"2026020501342148000_2026.01.09.698736v1.18","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/7.10.1555"},{"key":"2026020501342148000_2026.01.09.698736v1.19","doi-asserted-by":"publisher","DOI":"10.1080\/095530096145535"},{"key":"2026020501342148000_2026.01.09.698736v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/nature01368"},{"key":"2026020501342148000_2026.01.09.698736v1.21","doi-asserted-by":"crossref","first-page":"118137","DOI":"10.1016\/j.ejmech.2025.118137","article-title":"ATM inhibitors in cancer radiotherapy: Mechanisms, clinical development, and future directions","volume":"300","year":"2025","journal-title":"Eur J Med Chem"},{"key":"2026020501342148000_2026.01.09.698736v1.22","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat1719"},{"key":"2026020501342148000_2026.01.09.698736v1.23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1394"},{"key":"2026020501342148000_2026.01.09.698736v1.24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt055"},{"key":"2026020501342148000_2026.01.09.698736v1.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1129\/731522\/AM\/A-PHASE-IB-STUDY-OF-THE-DNA-PK-INHIBITOR"},{"issue":"3","key":"2026020501342148000_2026.01.09.698736v1.26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ijrobp.2023.09.024","article-title":"A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors","volume":"118","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026020501342148000_2026.01.09.698736v1.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2551"},{"key":"2026020501342148000_2026.01.09.698736v1.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0467"},{"key":"2026020501342148000_2026.01.09.698736v1.29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2026020501342148000_2026.01.09.698736v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006"},{"issue":"4","key":"2026020501342148000_2026.01.09.698736v1.31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1667\/RR15121.1","article-title":"Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15-18 October 2017; Cancun, Mexico","volume":"190","year":"2018","journal-title":"Radiat Res"},{"key":"2026020501342148000_2026.01.09.698736v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618"},{"key":"2026020501342148000_2026.01.09.698736v1.33","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28518"},{"key":"2026020501342148000_2026.01.09.698736v1.34","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292"},{"key":"2026020501342148000_2026.01.09.698736v1.35","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E08-08-0805"},{"issue":"8","key":"2026020501342148000_2026.01.09.698736v1.36","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026020501342148000_2026.01.09.698736v1.37","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S1470-2045(18)30096-2","article-title":"Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026020501342148000_2026.01.09.698736v1.38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96519"},{"issue":"1","key":"2026020501342148000_2026.01.09.698736v1.39","doi-asserted-by":"crossref","first-page":"6923","DOI":"10.1038\/s41467-024-51236-6","article-title":"Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy","volume":"15","year":"2024","journal-title":"Nat Commun"},{"key":"2026020501342148000_2026.01.09.698736v1.40","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0111"},{"key":"2026020501342148000_2026.01.09.698736v1.41","doi-asserted-by":"crossref","unstructured":"Jin, W.J. , et al., ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models. J Immunother Cancer, 2023. 11(9).","DOI":"10.1136\/jitc-2023-007474"},{"key":"2026020501342148000_2026.01.09.698736v1.42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1931"},{"key":"2026020501342148000_2026.01.09.698736v1.43","doi-asserted-by":"crossref","first-page":"120032","DOI":"10.1016\/j.biomaterials.2020.120032","article-title":"Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors","volume":"248","year":"2020","journal-title":"Biomaterials"},{"key":"2026020501342148000_2026.01.09.698736v1.44","doi-asserted-by":"crossref","unstructured":"Hingorani, D.V. , et al., Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs. Pharmaceutics, 2021. 13(3).","DOI":"10.3390\/pharmaceutics13030365"},{"key":"2026020501342148000_2026.01.09.698736v1.45","doi-asserted-by":"crossref","unstructured":"Mortaja, M. , et al., Tumor-Targeted Cell-Penetrating Peptides Reveal That Monomethyl Auristatin E Temporally Modulates the Tumor Immune Microenvironment. Molecules, 2024. 29(23).","DOI":"10.3390\/molecules29235618"},{"key":"2026020501342148000_2026.01.09.698736v1.46","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-1067"},{"issue":"5-6","key":"2026020501342148000_2026.01.09.698736v1.47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1039\/b904878b","article-title":"Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides","volume":"1","year":"2009","journal-title":"Integr Biol (Camb"},{"key":"2026020501342148000_2026.01.09.698736v1.48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408191101"},{"key":"2026020501342148000_2026.01.09.698736v1.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31601-z"},{"key":"2026020501342148000_2026.01.09.698736v1.50","doi-asserted-by":"crossref","unstructured":"Lesperance, J. , et al., Interactions of Antibody Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy. Adv Sci (Weinh), 2025: p. e06552.","DOI":"10.1002\/advs.202506552"},{"key":"2026020501342148000_2026.01.09.698736v1.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"2026020501342148000_2026.01.09.698736v1.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2"},{"key":"2026020501342148000_2026.01.09.698736v1.53","doi-asserted-by":"publisher","DOI":"10.1021\/bc0502917"},{"key":"2026020501342148000_2026.01.09.698736v1.54","doi-asserted-by":"publisher","DOI":"10.1038\/nature16057"},{"issue":"12","key":"2026020501342148000_2026.01.09.698736v1.55","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nchem.2635","article-title":"Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates","volume":"8","year":"2016","journal-title":"Nat Chem"},{"key":"2026020501342148000_2026.01.09.698736v1.56","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-3940"},{"key":"2026020501342148000_2026.01.09.698736v1.57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1821"},{"key":"2026020501342148000_2026.01.09.698736v1.58","doi-asserted-by":"crossref","unstructured":"Zhang, Q ., et al., Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer. JCI Insight, 2024. 9(6).","DOI":"10.1172\/jci.insight.168824"},{"issue":"5-6","key":"2026020501342148000_2026.01.09.698736v1.59","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1039\/b904890a","article-title":"In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer","volume":"1","year":"2009","journal-title":"Integr Biol (Camb"},{"key":"2026020501342148000_2026.01.09.698736v1.60","doi-asserted-by":"publisher","DOI":"10.1039\/C8CS00676H"},{"key":"2026020501342148000_2026.01.09.698736v1.61","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat1719"},{"key":"2026020501342148000_2026.01.09.698736v1.62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment","volume":"10","year":"2019","journal-title":"Front Immunol"},{"key":"2026020501342148000_2026.01.09.698736v1.63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67313"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.01.09.698736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:34:32Z","timestamp":1770284072000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.01.09.698736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":63,"URL":"https:\/\/doi.org\/10.64898\/2026.01.09.698736","relation":{},"subject":[],"published":{"date-parts":[[2026,1,12]]},"subtype":"preprint"}}